Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alzchem Group AGCHIX:ACTD 59 3-Year EPS without NRI Growth Rate is 34.70% as of Jun. 2026, which is 601% above its 10-year median of 4.95. GuruFocus rates CHIX:ACTD with a GF Score™ of 59/100 and a GF Value™ of €68.61 (Significantly Overvalued). Among 1,252 Chemicals companies, Alzchem Group AG ranks better than 86.26% on this metric.
During the past 12 months, Alzchem Group AG's average EPS without NRI Growth Rate was 17.50% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 34.70% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 26.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Alzchem Group AG was 34.70% per year. The lowest was -70.60% per year. And the median was 4.95% per year.
Alzchem Group AG (CHIX:ACTd) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Alzchem Group AG 3-Year EPS without NRI Growth Rate Related Terms
CHIX:ACTD vs LIN, SHW, ECL: 3-Year EPS without NRI Growth Rate Comparison
For the Specialty Chemicals subindustry, Alzchem Group AG's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alzchem Group AG 3-Year EPS without NRI Growth Rate vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Alzchem Group AG's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Alzchem Group AG's 3-Year EPS without NRI Growth Rate falls into.
Alzchem Group AG 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 34.70% mean?
Alzchem Group AG (CHIX:ACTD) has a 3-Year EPS without NRI Growth Rate of 34.70% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Alzchem Group AG and its competitors. This is 601% above median its historical median of 4.95. According to the industry distribution chart, Alzchem Group AG ranks #172 out of 1252 companies in the Chemicals industry, placing it in the top 13.7%.
Is Alzchem Group AG's 3-Year EPS without NRI Growth Rate too high?
Alzchem Group AG's current 3-Year EPS without NRI Growth Rate of 34.70% is 601% above median its 10-year median of 4.95. Based on the distribution chart, Alzchem Group AG ranks #172 out of 1252 companies in the Chemicals industry, which is in the top quartile — a strong position relative to peers. Overall, Alzchem Group AG has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alzchem Group AG's 3-Year EPS without NRI Growth Rate compare to LIN and SHW?
According to the Chemicals industry distribution chart, Alzchem Group AG ranks #172 out of 1252 companies for 3-Year EPS without NRI Growth Rate. This places Alzchem Group AG in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Chemicals company?
A good 3-Year EPS without NRI Growth Rate depends on the Chemicals industry context. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Alzchem Group AG and its competitors. Alzchem Group AG's current 3-Year EPS without NRI Growth Rate is 34.70%, which is 601% above median its own 10-year median of 4.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alzchem Group AG stock overvalued right now?
Based on GuruFocus' analysis, Alzchem Group AG (CHIX:ACTD) is currently considered Significantly Overvalued. The stock's GF Value™ is €68.61, compared to a current price of €177.05 — trading 158.1% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 34.70%, which is 601% above median its 10-year median of 4.95. Alzchem Group AG's overall GF Score™ is 59/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Alzchem Group AG (CHIX:ACTD), the current 3-Year EPS without NRI Growth Rate is 34.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alzchem Group AG (CHIX:ACTD) Overvalued in 2026?
Based on GuruFocus' analysis, Alzchem Group AG stock appears to be overvalued.
The current stock price of €177.05 is trading 158.1% above its estimated GF Value™ of €68.61.
GuruFocus considers Alzchem Group AG to be Significantly Overvalued.
Key valuation signals for CHIX:ACTD:
3-Year EPS without NRI Growth Rate: 34.70% (601% above median its 10-year median of 4.95)
GF Value™: €68.61 vs. price of €177.05 (158.1% above fair value)
No single metric tells the full story. See the CHIX:ACTD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alzchem Group AG is an international chemical company. The reportable segments of the company are Specialty Chemicals, Basics and Intermediates, and Other Holdings. The specialty chemicals segment focuses on the production and distribution of high-quality growth products, and the basics and intermediates segment covers the production of basic and intermediate products. It generates a majority of its revenue from the Specialty Chemical segment. Geographically it serves Europe, Asia, and the Rest of the world whilst deriving substantial revenue from European Union.
59GF Score
Get the complete analysis for CHIX:ACTD
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ACTD has been successfully added to your 
